Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.52 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PIK3R4 | Q99570 | 1/20 | 0.48 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | CDK1 | P06493 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089584 | 0.84 | PIK3CD (0.54) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL9957787 | 0.84 | PIK3C3 (0.61) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL9956188 | 0.84 | PIK3CD (0.54) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL9957195 | 0.81 | PIK3C3 (0.79) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL9957034 | 0.71 | PIK3C3 (0.68) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL9957247 | 0.69 | PIK3C3 (0.83) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL9957785 | 0.69 | PIK3C3 (0.83) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL9957623 | 0.69 | PIK3C3 (1.00) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL28794435 | 0.69 | GSK3B (0.58) | PIK3CAPIK3CBPIK3CGGSK3BMAPT | |
| SCHEMBL9956230 | 0.67 | PIK3C3 (0.79) | PIK3C3PIK3CDPIP5K1CPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2655340-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | Novartis AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | PIK3C3 210/4885PIK3CD 39/4885PIP5K1C 229/4885 |
| US-20130338159-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | PIK3C3 263/4885PIK3CD 36/4885PIP5K1C 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.